Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia

Leukemia

Volumn 29, Issue 5, 2015, Pages 1206-1209

  Rea, D ^a   Mirault, T ^b,c   Raffoux, E ^a   Boissel, N ^a   Andreoli, A L ^a   Rousselot, P ^d   Dombret, H ^a   Messas, E ^b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; BRAIN ISCHEMIA; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGED; ALGORITHM; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE FREE SURVIVAL; EUROPE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929289997     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.342     Document Type: Letter

References (15)

1. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
2. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117: 1141-1145.
3. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
4. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer- Hohendanner G, Sillaber C et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86:533-539.
5. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347-1348.
6. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316-1321.
7. Saglio G, Hochhaus A, Hughes TP, Clark RE, Lipton JH, Pasquini R et al. ENESTnd update: Nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood (ASH Annual Meeting Abstracts) 2013; 122: abstract 92.
8. Emir H, Albrecht-Schgoer K, Huber K, Grebien F, Eisenwort G, Schgoer W et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood (ASH Annual Meeting Abstracts) 2013; 122: abstract 257.
9. Racil Z, Razga F, Drapalova J, Buresova L, Zackova D, Palackova M et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 2013; 98: e124-e126.
10. Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 2014; 99: 1197-1203.
11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635-1701.
12. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872-884.
13. Murray CJL, Lopez AD. Measuring the global burden of disease. New Engl J Med 2013; 369: 448-457.
14. Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematol Am Soc Hematol Educ Program 2013; 2013: 168-175.
15. Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica 2011; 96: 1457-1461.